| Market Capitalization (Millions $) |
36 |
| Shares
Outstanding (Millions) |
101 |
| Employees |
832 |
| Revenues (TTM) (Millions $) |
180 |
| Net Income (TTM) (Millions $) |
-122 |
| Cash Flow (TTM) (Millions $) |
10 |
| Capital Exp. (TTM) (Millions $) |
0 |
Fibrogen Inc
Fibrogen Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative therapies for the treatment of serious and life-threatening medical conditions. The company was founded in 1993 and is headquartered in San Francisco, California. Fibrogen's pioneering research addresses unmet medical needs in areas such as anemia, fibrosis, and cancer.
Fibrogen's flagship product is roxadustat, a first-in-class oral treatment for anemia in patients with chronic kidney disease. Roxadustat is an hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that increases endogenous erythropoietin levels and enhances iron uptake. Roxadustat is currently approved in China and Japan for the treatment of anemia caused by chronic kidney disease, and the company is pursuing regulatory approval in other markets, including Europe, the United States, and Canada.
In addition to its work on roxadustat, Fibrogen is also developing therapies for other indications. Pamrevlumab, a monoclonal antibody targeting connective tissue growth factor (CTGF), is being evaluated for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy. FG-5200, a gene therapy for cystic fibrosis, is being developed in collaboration with Astellas Pharma.
Fibrogen has an extensive research and development pipeline, with a number of programs in preclinical and clinical stages. The company has partnerships with leading pharmaceutical companies such as AstraZeneca, Astellas, and Bristol-Myers Squibb to develop and commercialize its products. Fibrogen's expertise in hypoxia-inducible factor biology and fibrosis has led to the discovery of novel targets and transformative therapies for unmet medical needs.
Fibrogen has a strong financial position, with a market capitalization of approximately $7 billion as of June 202 The company has over 4,000 employees worldwide and operates research and manufacturing facilities in the United States, China, and Sweden. Fibrogen is committed to research, development, and commercialization of treatments for debilitating and life-threatening diseases, and its innovative therapies have the potential to significantly improve the lives of patients globally.
Company Address: 350 Bay Street San Francisco 94158 CA
Company Phone Number: 978-1200 Stock Exchange / Ticker: NASDAQ FGEN
|
0.08% 